Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
3.705
+0.145 (4.07%)
At close: Aug 17, 2026, 4:00 PM EDT
3.770
+0.065 (1.75%)
After-hours: Aug 17, 2026, 7:55 PM EDT

Zentalis Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Zentalis Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $6.89. The average 1-year stock price forecast is 85.96% higher than the current stock price, while the lowest is $4.00 (+7.96%) and the highest is $10 (+169.91%).

Price Target: $6.89 (+85.96%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$4.00$6.89$6.00$10
Change+7.96%+85.96%+61.94%+169.91%

Analyst Ratings

The average analyst rating for Zentalis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy444455
Buy000000
Hold555555
Sell000000
Strong Sell000000
Total99991010

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Mizuho Securities
Mizuho Securities
Buy
Reiterates
$8
BuyReiterates$8+115.92%Aug 11, 2026
Morgan Stanley
Morgan Stanley
Hold
Reiterates
$4$5
HoldReiterates$4$5+34.95%Aug 7, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$10
BuyMaintains$10+169.91%Aug 7, 2026
Guggenheim
Guggenheim
Buy
Maintains
$10
BuyMaintains$10+169.91%Aug 7, 2026
Rodman & Renshaw
Rodman & Renshaw
Buy
Initiates
$11
BuyInitiates$11+196.90%Jul 23, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
16.38M
EPS This Year
-2.11
from -1.80
EPS Next Year
-1.80
from -2.11
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
---67.43M--
Gross Profit
---67.43M--
Gross Margin
---100.00%-82.00%
Operating Income
-207.74M-227.29M-248.99M-187.46M-140.88M-172.77M
Net Income
-158.73M-236.81M-292.19M-165.84M-137.06M-165.30M
EPS
-----1.80-2.11
Free Cash Flow
-89.16M-88.02M-86.97M-67.10M-75.87M-159.65M
No. Analysts
-----9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-1.37
Avg-2.11
Low-2.39

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-